David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida.

Moderator: Robert Rifkin, MD
Participants: Corey Cutler, MD; Pere Gascon, MD, PhD; Mark McCamish, MD, PhD

This program is supported by Sandoz Inc.

Multiple Myeloma

S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.

Lymphoma

John Leonard, MD

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

John Leonard, MD, of Weill Cornell Medical College, discusses this phase II study of R-CHOP with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma (Abstract 811).

Leukemia

James Foran, MD

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).

Lymphoma

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data (Abstract 254).

Jan

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

ACS Guidelines for Cervical Cancer Self-Collected HPV Testing Now Included

Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL

Prostate Cancer: Novel PSMA-Targeted Radioligand Shows Reduced Salivary Gland Uptake in Preclinical Studies

CD123-Targeting ADC Shows Activity in AML and BPDCN

New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML